Cilnidipine's Renoprotective Effects in CKD Patients

Guidelines and Recommendations

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend that many CKD patients will require combination therapy to achieve target blood pressure of <120 mmHg systolic 1, 2
• The KDIGO guidelines prioritize renin-angiotensin system inhibitors (ACEi or ARB) as first-line therapy for CKD patients with albuminuria, and calcium channel blockers are often needed as part of combination therapy 3, 4
• The European Society of Cardiology (ESC) guidelines for hypertension management recommend RAS blockers as more effective at reducing albuminuria than other antihypertensive agents in CKD patients, but CCBs are important add-on therapy 5

Monitoring and Safety

• Check serum potassium and creatinine within 2-4 weeks after initiating therapy, particularly when combined with RAS blockers 6
• Avoid dual RAS blockade (combination of ACEi, ARB, or direct renin inhibitor) when using any CCB, as this increases adverse effects without additional benefit 3, 6